The structural complexity of many natural products sets them apart from common synthetic drugs, allowing them to access a biological target space that lies beyond the enzyme active sites and receptors targeted by conventional small molecule drugs. Naturally occurring cyclic peptides, in particular, exhibit a wide variety of unusual and potent biological activities. Many of these compounds penetrate cells by passive diffusion and some, like the clinically important drug cyclosporine A, are orally bioavailable. These natural products tend to have molecular weights and polar group counts that put them outside the norm based on classic predictors of "drug-likeness". Because of their size and complexity, cyclic peptides occupy a chemical "middle space" in drug discovery that may provide useful scaffolds for modulating more challenging biological targets such as protein-protein interactions and allosteric binding sites. However, the relationship between structure and pharmacokinetic (PK) behavior, especially cell permeability and metabolic clearance, in cyclic peptides has not been studied systematically, and the generality of cyclic peptides as orally bioavailable scaffolds remains an open question. This review focuses on cyclic peptide natural products from a "structure-PK" perspective, outlining what we know and don't know about their properties in the hope of uncovering trends that might be useful in the design of novel "rule-breaking" molecules.
INTRODUCTION
High-throughput -omics technologies (e.g., shRNA and expression profiling, deep sequencing, proteomics, metabolomics) have delivered vast datasets for biologists to mine for new clues into the molecular basis of disease. One result of these efforts has been the emergence of a new genseration of candidate drug targets. Unlike typical enzymes and receptors, many of these potential targets are signaling proteins and transcription factors whose functions are carried out through protein-protein or protein-DNA interactions [1] . Since few of these biomolecules have endogenous lowmolecular weight ligands, finding traditional, drug-like small molecules that can modulate their functions represents a major challenge ahead. Medicinal chemists are therefore charged with the task of identifying scaffolds that are large and complex enough to bind macromolecular interfaces and non-canonical allosteric binding sites, but yet retain druglike membrane permeability and metabolic stability.
It is our view that cyclic peptides, especially those of natural origin, offer strategic insights into this design problem. Many cyclic peptide natural products are biosynthesized by non-ribosomal peptide synthetases (NRPSs), which, unlike the ribosome, often utilize as substrates both regular and non-proteinogenic amino acids. NRPSs also often incorporate "tailoring" activities such as epimerization, Nmethylation, and heterocyclization [2] , further increasing the diversity of these natural products. And like other natural membrane permeable, tend to be cleared more quickly by CYPs in the liver, whereas compounds that are hydrophilic enough to survive clearance may not be permeable enough to reach circulation in the first place. As with permeability, QSAR models of clearance are generally based on training sets comprised of typical small molecules [7] , and so predicting the clearance of large, "non-Lipinski" molecules remains a challenge.
Cyclization in peptides eliminates charged termini, which can favor both membrane permeability [8] and metabolic stability [9] . Cyclization is also thought to minimize conformational entropy losses upon target binding, although some studies have shown the impact of cyclization on binding entropy to be more complex than conventional wisdom suggests [10, 11] . Nevertheless, while cyclization may improve the PK properties of peptides in general, the systematic design of orally bioavailable cyclic peptide therapeutics (e.g. CSA) will require a deeper understanding of the impact of structure on physicochemical properties in these non-"druglike" molecules. This in turn will require more direct and systematic investigations into the PK properties of these remarkable compounds, including cell-based permeability and absolute oral bioavailability studies. This review examines cyclic peptide natural products from a PK perspective, with an emphasis on those molecular properties and structural motifs that might be emulated in the design of novel synthetic inhibitors against the next generation of protein targets.
Cyclic Peptide Natural Products Classified by Physical Properties
Cyclic peptide natural products can be grouped into the following categories based on a broad survey of their structures and known biological functions: 1) Highly charged molecules (polycationic and polyanionic) that function mostly as antimicrobial agents by disrupting bacterial membranes; 2) Non-polar cyclic peptides that contain mostly lipophilic side chains and modifications to the amide backbone (e.g., N-methylation) and are likely to penetrate eukaryotic cells by passive diffusion; 3) Cyclic peptides of mixed polarity, most of which are amphiphilic but are not limited to microbial targets; 4) Cyclotides and cysteine-knot proteins, which are small (2-8 kD) proteins with unusual topologies that can show remarkable oral activity.
Within each of these categories, cyclic peptides can be organized into three main sub-groups based on structure/topology: 1) homodetic, cyclized from head-to-tail; 2) heterodetic, cyclized between side chains or from a side chain to one of the termini; and 3) complex, comprised of a mixture of homodetic and heterodetic linkages (Fig. 1) . Many heterodetic cyclic peptides have a "lariat" structure formed by cyclization of the C-terminal carboxylic acid onto a side chain, typically via a lactam linkage through a lysine or ornithine residue, or a lactone linkage through serine or threonine. Heterodetic cyclic peptides can also be capped on their amino termini with a lipid tail of varying length and composition. Compounds in the "complex" category include bicyclic peptides and cyclic peptides with knot topologies. Fig. (1) . The three main sub-groups of cyclic peptides based on structure: a) homodetic, b) heterodetic, c) complex.
Cationic Antimicrobial Peptides
The cationic antimicrobial peptides (AMPs) comprise a diverse group of compounds whose activities are associated primarily with their ability to interact with and, in many cases, form pores in bacterial membranes (Fig. 2) . Most AMPs are aphiphilic peptides that disrupt negatively charged microbial membranes with varying selectivity depending on the structure of the AMP. While some natural AMPs are cyclic, many are linear peptides that adopt various secondary structures upon their interaction with membranes. Despite much evidence that AMPs exert their antimicrobial activity by disrupting membranes, some cationic AMPs have potent antimicrobial activity without disrupting membranes, and some have activities that are associated with inhibition of intracellular targets [12] . Nevertheless, these compounds are not orally bioavailable and tend to show selectivity toward bacterial membranes. Their structures and activities have been reviewed elsewhere [12] [13] [14] and will not be taken up further here. 
Non-Polar Cyclic Peptides
Cyclic peptide natural products that are comprised of mostly neutral, lipophilic side chains and few if any polar residues can be classified as "non-polar" cyclic peptides. These cyclic peptides and depsipeptides exhibit a wide range of biological activities, many of which are associated with intracellular targets in eukaryotes ( Table 1 ). Although the cell permeabilities of few of these compounds have been investigated directly (e.g., by quantifying diffusion across Caco-2 or other epithelial cell lines), many are assumed to be cell permeable based on an observed correlation between direct in vitro binding and/or activity data and activity in cell-based assays. Because they do not interact with membranes electrostatically, these compounds are thought to penetrate membranes via the same classical transcellular route ascribed to most small molecule drugs. However, until detailed in vitro studies are performed to evaluate their mechanism(s) of cell penetration, such hypotheses remain purely speculative. The archetype of the nonpolar cyclic peptides is the immunosuppressive natural product cyclosporine A, a cyclic undecapeptide with a molecular weight of ~1200 that has an oral bioavailability in humans of 29% and is passively permeable [15] . The high molecular weights of these compounds compared with traditional small molecule drugs make them excellent model systems for studying the role of structure in passive membrane permeability. Our lab has investigated synthetic cyclic peptides inspired by these natural products to gain a better understanding of the chemical features driving their unusual PK properties. We have shown using simple model systems that the ability to form intramolecular hydrogen bonds in low dielectric media correlates with passive membrane diffusion [8, 16] . We have also observed that N-methylation patterns that facilitate the formation of transannular hydrogen bonds are associated with good passive permeability and oral bioavailability [17] . This result is corroborated by many examples of cyclic peptide natural products whose structures have been solved, either by NMR in low dielectric solvents or in the solid state, or in some cases both. Many of these peptides contain multiple Nmethyl and/or Pro residues, and most have extensive intramolecular hydrogen bond networks that sequester polar amide groups in the low dielectric of the membrane. While the total hydrogen bond donor and acceptor counts put most compounds in this class out of compliance with Lipinski's Rule (<5 donors and <10 acceptors), the number of free, non-hydrogen bonded donors and acceptors puts them well within the acceptable range ( Table 2 ). Although they contain many rotatable bonds and have molecular weights in the ~800-1500 range, solution NMR data suggest that these compounds are relatively rigid, especially in low dielectric media. In this sense, their membrane permeability is consistent with the observation by Veber, et al., that rigidity is a better predictor of bioavailability than molecular weight [18] . In that retrospective study, the number of rotatable bonds (which has a roughly linear relationship with MW) was a better predictor of bioavailability than MW. Although the number of rotatable bonds in natural macrocycles may be high, they remain relatively rigid due to constraints imposed by cyclization and local nonbonded interactions.
Non-polar cyclic peptides are characterized by a predominance of aliphatic residues, the presence of D-amino acids, and N-methylation of backbone amides. If they are present, polar residues often form hydrogen bonds between the side chain and backbone, for example in the cases of argyrin B, aureobasidin, and guangomide A (Fig. 3) . Few if any cyclic peptides in this category have ionizable side chains, and they rarely contain highly polar neutral residues such as Gln and Asn.
The cyclic peptides in this category whose crystal structures have been solved often contain one or more -turns that template various patterns of intramolecular hydrogen bonds. These -turns are defined by a transannular hydrogen bond between the i and i + 3 residues, while the stereochemistry, N-methylation status, and side chain functionality of the i + 1 and i + 2 residues provide the phi and psi restraints that template the turn. Detailed reviews of various subtypes of turns found in proteins [19, 20] and peptides [21] , and the residues that favor their formation, have been published. Many of these turns contain Pro and/or Gly residues and Damino acids, all of which favor -turns when present at both the i + 1 or i + 2 positions. Both Pro and N-methyl residues can adopt the cis-amide conformation, which, when located at i + 2, induces the type VI -turns found in many neutral cyclic peptide natural products.
Homodetic Non-Polar Cyclic Peptides
The homodetic non-polar cyclic peptides can be further classified into four major categories defined by the types of residues and backbone modifications that they contain: regular (all-amide) peptides, depsipeptides, pattelamide-like peptides, and proline-rich peptides. Examples of regular nonpolar cyclic peptides are argyrin B, cyclomarin, and CSA (Figs. 3 and 4) . Most of the cyclic peptides in this category contain multiple N-methyl residues, yet very few are permethylated. This trend is consistent with work in our lab showing that permethylation can decrease membrane permeability relative to specific patterns of N-methylation that favor intramolecular hydrogen bonds [17] . Indeed, for those peptides in this class whose structures are known, the vast majority of non-N-methylated amides are involved in transannular hydrogen bonds. While this simple hypothesis is consistent with many cyclic peptide structures (vide infra), other work using similar model systems suggests a more complex role of N-methylation in the active transport of cyclic peptides [22] [23] [24] [25] . Recent reviews treat N-methylation in peptides from synthetic and conformational perspectives [22, 26] .
CSA is an 11-amino acid, homoetic non-polar cyclic peptide that contains seven N-methyl groups, a single D-amino acid, and a non-proteinogenic prenylated Thr residue. CSA is a clinically used immunosuppressive agent that binds the prolyl cis-trans isomerase cyclophilin. The resulting CSA/cyclophilin complex is a potent inhibitor of calcineurin, 
a central phosphatase involved in T-cell activation [27] . Thus, CSA has the unusual function of inducing an inhibitory protein-protein interaction. The structure of CSA has been determined both in the free state, by X-ray crystallography and NMR [28, 29] , and in the ternary complex with cyclophilin and calcineurin [30] . In the free state, in both the crystal structure and the NMR solution structure in CDCl 3 , CSA adopts a rectangular conformation characterized by three transannular hydrogen bonds and an external, -turn forming hydrogen bond (Fig. 4a) . In contrast, in the crystal structure of the ternary complex with cyclophilin and calcineurin, CSA adopts a more open conformation in which many of the polar groups point outward, forming intermolecular hydrogen bonds with both protein partners ( Fig.  4b ) [30] . Interestingly, the non-polar conformation of CSA observed in CDCl 3 was also significantly populated in 50% aqueous methanol [31] . This type of conformational flexibility may be common to nonpolar cyclic peptides and has been identified in at least two other cases (see below). Whether this behavior contributes to the unexpected passive permeability of this class has not been examined directly.
The homodetic non-polar cyclic depsipeptides have at least one depsi-(i.e., lactone) linkage and include compounds such as destruxin B, aureobasidin A, HUN-7293/CT08, and guangomide A (Fig. 3) . Whether these lactone linkages serve a critical role in the pharmacokinetic properties of these molecules has not been studied systematically, although their prevalence among natural cyclic peptides of disparate origins suggests that the lactone, like Nmethylation, may serve an important role in enhancing the permeability and/or stability of these compounds.
A well-known cyclic peptide natural product is the K + ionophore valinomycin, a cell-permeable and cytotoxic cyclic depsipeptide that acts as a mitochondrial uncoupler by facilitating the passive diffusion of potassium ions across the mitochondrial inner membrane (Fig. 5) . The apo-form of valinomycin crystallized from octane shows a rectangular geometry in which all of the amide NH groups are involved in trans-annular hydrogen bonds. These hydrogen bonds define -turns between the lactic acid C=O groups and the valine NH groups at i and i + 3, respectively (Fig. 5b) [32] . In complex with K + , the molecule rearranges and adopts a toroidal geometry using a different arrangement of turns in which six of the C=O groups point toward the K + in the center of the torus (Fig. 5c) [33] . In both the apo-form and the K + complex, all six of the NH groups are involved in transannular hydrogen bonds, but the two structures have very different H-bonding arrangements. In yet another conformation (crystallized from DMSO in the absence of K + ) that might be considered a model for its aqueous, apo state, valinomycin adopts a flat, triangular conformation in which three of the amide N-H groups are solvent-exposed, while the remaining three N-H groups point inward forming type II -turns (Fig.  5d) .
The K D between valinomycin and K + is 1-3 mM in aqueous solution [34] , significantly higher than environmental levels but 10-fold lower than the concentration of K + in the mitochondrion, suggesting that in order to function as an uncoupler, valinomycin must be cell permeable in both its apo-and K + -complexed forms. That it is able to adopt lipophilic conformations in both complexed and uncomplexed forms points toward a mechanism of passive diffusion, while the "open" conformer may account for its water solubility in the apo form. Indeed, valinomycin dissolves in solvents ranging in polarity from water to hexane [34] .
Heterodetic Non-Polar Cyclic Peptides
Many non-polar cyclic peptides have heterodetic linkages and include compounds such as coibamide A, didemnin B, YM254890, selenamide, luzopeptin, and callynormine A. Didemnin B (Fig. 3e) is a non-polar lariat cyclic peptide that potently inhibits protein synthesis by binding to the eukaryotic translation elongation factor EF-1 [35] [36] [37] . It has lownM activity in cells and was the first marine natural product to enter human clinical trials. Although clinical trials of didemnin B were discontinued due to toxicity and low efficacy, the nearly identical compound aplidin (Fig. 3 , also called plitidepsin) has shown promise in phase II/III clinical trials against a variety of cancers [38, 39] . Aplidin has been the subject of in vitro metabolism [40] and in vivo i.v. pharmacokinetics studies and has lower plasma half-life [41] (44 h vs. 0.14 h) and lower cardiotoxicity [42] than didemnin B. No direct cell permeability or oral bioavailability data have been reported for didemnin B or aplidin. drodiaminopropionic acid group linking the cyclic octapeptide portion with the short tripeptide tail (Fig. 3c) . While callynormine contains no N-methyl residues, the crystal structure shows multiple hydrogen bonds both within the ring and between the ring and the tail [43] . The lariat depsipeptide coibamide (MW 1288) also contains 11 amino acids, with 7 residues in the ring and 4 in the tail, and shows low nM cytotoxicity in various human cancer cell lines. Coibamide exhibited an unusual COMPARE fingerprint in the NCI60 cell line screen, suggesting that it has a unique biological target or MOA. In contrast to callynormine A, coibamide is extensively N-methylated both in the tail and in the cyclic portion. Although its three-dimensional structure is unknown, its bioactivity and N-methylation pattern are consistent with cell permeability by the same mechanism(s) associated with other members of this family.
Luzopeptin is a heterodetic cyclic peptide that contains two pendant aromatic 3-hydroxy-6-methoxyquinaldic acid groups. It has C2 symmetry and binds to DNA by intercalating both chromophores in a staple-like fashion with the macrocycle sitting in the major groove. In both the X-ray crystal structure [44] and the NMR structure in CDCl 3 [45] , the free compound has a collapsed, rectangular structure with intramolecular hydrogen bonds between the Gly NH and the sarcosine carbonyl groups, and between the OH groups of the hydroxyvalines to their own carbonyls. In the DNAbound form, luzopeptin adopts a square conformation in which the Gly NH groups and the hydroxyvaline carbonyls form hydrogen bonds with bases in the major groove [46, 47] .
YM-254890 is another potently bioactive heterodetic cyclic peptide that was first identified as an inhibitor of ADPinduced platelet aggregation [48] . This compound was subsequently shown to inhibit signaling through G q , a subfamily of the heterotrimeric guanine nucleotide-binding proteins (G proteins) that transduce signals from ligand-activated Gprotein coupled receptors (GPCRs). An activated GPCR stimulates the GDP-to-GTP exchange in a G protein inside the cell, causing the dissociation of G from its associated G subunit. The free G and G subunits each bind and activate various downstream effectors, which, for the G q subtype, is phospholipase C. The cyclic peptide YM-254890 binds to G q and prevents the exchange of GDP for GTP, locking the G q subunit in its "off" state [49] . The X-ray crystal structure (of FR900359, a close structural analog of YM-254890) [50] reveals a complex network of intramolecular hydrogen bonds involving all four free amide NH groups and the -OH group of the -hydroxyleucine residue (Fig.  4e) . The molecule undergoes a major conformational rearrangement upon target binding such that, in the bound conformation, most of the polar groups point away from the ring forming hydrogen bonds with the protein, with a new intramolecular hydrogen bond formed within the macrocycle (Fig. 4f) [49] . Both luzopeptin and YM-254890 are presumed to be cell permeable based on their nM potencies in both in vitro and in cell-based assays and the congruence between their cellular phenotypes and in vitro activities, although their cell permeabilities have not been measured directly.
Could the favorable PK properties such as good permeability and low clearance of the non-polar cyclic peptides relate in general to their ability to equilibrate between open, hydrophilic conformers in water and closed, hydrophobic conformers in the membrane? For example, if CSA could be locked into its low-dielectric conformation so that it could not equilibrate into its "open" conformer in aqueous solution, what impact would it have on clearance, permeability, and solubility? How general and/or important is conformational flexibility in determining the ADME properties of neutral cyclic peptides? The impact of such conformational dynamics on permeability and solubility has not been investigated using well-controled model systems, suggesting that more systematic studies are needed in this area.
One study that may shed light on the relationship between structure and cell permeability found that the permeability of CSA in Caco-2 increased by two orders of magnitude over the temperature range from 5 to 37˚C [51] . Equilibrium sedimentation studies showed a similarly dramatic increase in the partial specific volume of CSA over the same range, and a corresponding decrease in its aqueous solubility. Importantly, these authors found that the equilibrium distribution of conformers in aqueous solution remained constant over the same temperature range, suggesting that the observed increase in permeability was not due to a corresponding increase in the relative abundance of the internally hydrogen bonded conformer at the higher temperature. Like CSA, the permeabilities of salicylic acid and propranolol (two other drugs that penetrate membranes by passive diffusion) also increased with increasing temperature, although for these drugs the effect was an order of magnitude less pronounced than that of CSA. These data suggest that the classical, entropy-driven hydrophobic effect drives the energetics of membrane permeability for CSA. Could the ability to adopt open, hydrophilic conformers in aqueous solution serve to prevent aggregation in large, non-polar cyclic peptides like CSA? Since non-specific, hydrophobic aggregation is presumably also entropically driven, any advantage gained with an increase in non-polar surface area would be counteracted by a tendency to aggregate. Equilibration among "open" hydrophilic conformers would therefore disfavor aggregation in large, non-polar solutes by decreasing the relative concentration of the "lipophilic" conformer compared to more water-soluble ones. Furthermore, how does the size-dependent diffusion coefficient, a factor that predicts decreasing permeability with increasing cross-sectional area [52, 53] , factor into the permeability equation in opposition to the classical hydrophobic effect? Applying similar experimental techniques to other cyclic peptides could help tease apart the contributions of each of these factors in determining the membrane permeability of large macrocycles.
Patellamide-Like Cyclic Peptides
While most nonpolar cyclic peptides are biosynthesized by NRPSs, the patellamide-like cyclic peptides are derived from ribosomally synthesized sequences of alternating lipophilic and Ser, Thr, or Cys residues. These hydroxyl-and sulfhydryl-containing residues are precursors of the oxazoline and thiazoline rings that characterize this class of natural products, formal products of the cyclodehydration between the side chain -OH or -SH groups and the neighboring i -1 backbone carbonyl group. Oxidation of the oxazoline and thiazoline rings leads to the corresponding aro-matic oxazoles and thiazoles. Examples of the pattelamidelike cyclic peptides include lissoclinamide 7, patellamide D, and ascidiacyclamide (Fig. 6) . Some of these, such as the patellamides and ascidiacyclamide, are comprised exclusively of these backbone-cyclized residues, while others, such as trunkamide, are hybrids and contain one or more unmodified residues. While the pure patellamide-like peptides rarely contain N-methyl groups, consistent with their ribosomal origin, they generally exhibit multiple intramolecular hydrogen bonds, either between the 5-membered ring nitrogen lone pair and the neighboring N-H group, or, in some cases, between NH groups and C=O groups within the molecule. Patellamides and ascidiacyclamide can adopt a square conformation in which the NH groups point into the center of the ring, or a twisted " Figure  eight" conformation in which the thiazole rings are stacked and the structure is stabilized by transannular hydrogen bonds. Which of these conformations a particular patellamide adopts appears to be determined by the nature of the Rgroups on the carbons, with the square conformation being preferred by C2-symmetric arrangements of R-groups and the twisted conformation favored by asymmetric arrangements of R-groups. Although there was one report that lissoclinamide 7 exhibits nM cytotoxicity in some cell lines [54] , this degree of toxicity was not recapitulated in a screen by the NCI [55] . Other peptides in this family have failed to show appreciable cytotoxicity or any other significant biological activity, leading to the speculation that they act as multivalent cation transporters or play some other role in the metabolic maintenance of the producing organism. 
Proline-Rich Cyclic Peptides
The phakellistatins [56] [57] [58] (Fig. 7) are examples of homodetic proline-rich cyclic peptides. These rarely contain Nmethyl residues, although many of them have extensive networks of internal hydrogen bonds. These peptides are associated with various bioactivities, although, similar to the patellamide-like peptides, their potencies are moderate, at least in the assays in which they have been screened to date.
Hybrid Polyketide-Polypeptide Macrocycles
Conjoined NRPS and polyketide synthase (PKS) modules yield a diverse class of macrocycles comprised of both polyketide and polypeptide fragments [59] [60] [61] . These compounds display impressive backbone variety and complexity, pushing beyond the limits of the 20 proteinogenic amino acids (and modifications thereof) by incorporating polyketide fragments of varying lengths and functionality. Such scaffolds are biosynthesized in modular fashion by hybrid PK-NRPS Claisen-like mechanisms forming backbone alkene and -hydroxy functionality. These molecules commonly possess a polypeptide hemisphere and a polyketide hemisphere, the latter consisting of a carbon chain with multiple stereocenters defined by pendant methyl and hydroxyl groups and endocyclic double bonds. Fig. (7) . Proline-rich cyclic peptide phakellistatin 8.
Apratoxin A (Fig. 8a) is one such 25-member hybrid polyketide-polypeptide macrocycle. Isolated from the marine cyanobacterium Lyngbya majuscula, this secondary metabolite exhibits potent activity against human solid tumor cell lines (KB IC 50 = 0.52 nM, LoVo IC 50 = 0.36 nM) and has shown marginal activity in vivo against colon and mammary cancer [62] . More recent studies have shown that apratoxin A modulates cotranslational translocation [63] , although other evidence points toward a mechanism involving association with Hsp/Hsc70 and subsequent stimulation of chaperonemediated autophagy of specific client proteins [64] . No intramolecular hydrogen bonding was observed via CDCl 3 NMR and subsequent molecular dynamics minimization [62] . Jasplakinolide (Fig. 8b) is a 19-member polyketide cyclodepsipeptide hybrid isolated from the marine sponge Jaspis. The backbone is composed of a -Tyr, N-Me bromoTrp, and Ala tripeptide coupled to a 12-carbon alkenecontaining polyketide fragment cyclized through an ester linkage. The natural product exhibits anti-proliferative activity in human cell lines [65, 66] and is one of the few cell permeable small molecules known to stabilize F-actin [67] , binding competitively at the phalloidin site with a K d of 15 nM [68] . The solution and crystal structures display no intramolecular hydrogen bonding [69] , although the skeleton is quite flexible, capable of adopting several conformations as a result of the long carbon polyketide fragment [70] . Jasplakinolide has long been presumed to be cell permeable based on the correspondance between its actin-stabilizing activity in vitro and its dramatic effect on the cytoskeleton in living cells. Its cell permeabilty was confirmed directly, however, in a recent report that used synthetic fluorescent probes of jasplakinolide to image the actin cytoskeleton in live cells [71] .
The complex skeletons of hybrid polyketide-polypeptide macrocycles permit the molecules to adopt conformations that are not available to strictly peptide-based scaffolds. The lack of intramolecular hydrogen bonding in the few molecules of this class whose 3-D structures have been characterized suggests that perhaps the hydrophobic nature of the polyketide segment is able to compensate for the polarity imparted by the non-N-methylated amides. However, it should be noted that the mechanism of membrane penetration of these compounds has not been investigated explicitly. 
Cyclic Peptides of Mixed Polarity
The various membrane-disrupting and membranepenetrating mechanisms attributed to the amphiphilic antimicrobial peptides are primarily physical in nature, that is, their MOAs do not depend on inhibition of specific macromolecules. In contrast, there is a class of cyclic peptide natural products that are amphiphilic and yet exhibit activities in mammalian cells that point toward intracellular targets and PK profiles that suggest passive membrane diffusion. These cyclic peptides of mixed polarity encompass a variety of structural types and biological activities. For example, kahalilide F [72] (KF; Fig. 9a) , is a 13-amino acid cyclic lariat peptide (C-terminal-to-Thr linked) that is potently cytotoxic in human cells (EC 50~1 00 nM) with good selectivity for tumor cells vs. primary human cells [73] . Although its biological activity has been the subject of intense study [73] [74] [75] [76] , the target and mechanism of action (MOA) remain obscure.
The cyclic portion of KF contains 6 residues and is neutral except for a single Orn residue, with a relatively short, 6-carbon aliphatic cap at the N-terminus of the 7-residue tail. While the mechanism of internalization of kahalalide F is unknown, its rapid effect on endosome morphology suggests that its target may be associated with intracellular membrane compartments [76] . Fluorescent [77] and gold nanoparticle [78] conjugates of KF were localized to endosomal compartments, and KF itself causes dramatic swelling of lysosomes [76] followed by severe disruption of organelle architecture and cell death via a non-apoptotic mechanism [73] . KF was also stable to proteolysis and oxidative metabolism in vitro in the presence of pooled human plasma and liver microsomes [79] , consistent with its in vivo stability.
Human PK studies [80] [81] [82] [83] showed a rapid clearance from plasma following i.v. infusion, with a steady state volume of distribution (V ss ) of ~7 L/kg, indicative of low distribution in tissues. Whether this V ss value is a function of poor cell permeability or high plasma protein binding was not determined.
Perhaps reflecting the deleterious effect of highly polar substituents on passive membrane diffusion, many polar cyclic peptides have a lipid appendage. Examples in this group include largamide, pseudodesmin A, and the papuamides (Fig. 9b-f) . Pseudodesmin A is a member of a family of "cyclolipeptides" (CLPs) derived from Pseudomonas spp. characterized by a lipid tail appended to an oligopeptide macrocycle cyclized through a depsi-linkage to a Thr side chain [84] . The crystal structures of several members of this class have been solved, including pseudodesmin A [85] , WLIP [86] , pseudophomin [87] , amphisin [88] , and tensin [89] , and all adopt a similar conformation in which one half of the macrocycle is folded into a left-handed -helix stabilized by a network of intramolecular hydrogen bonds (Fig. 9d) . The lipid tail is extended along one side of the macrocycle with the lipophilic residues, while the hydrophilic residues project from the opposite side of the macrocycle, creating an amphiphilic geometry (Fig. 9d, e) . Overall, the biological activity of these compounds in various antimicrobial screens is mild to moderate [84] , and little has been reported on their effects, if any, on mammalian cells. Further, the mechanism(s) by which these molecules interact with and/or penetrate membranes has not been studied directly.
Papuamide A protects cells against HIV-induced toxicity by interfering with viral entry, with an EC50 of ~100 nM [90] . The very similar papuamide B (Fig. 9f) was shown to interact with membranes in S. cerevisiae by specific binding to phosphatidylserine (PS) [91] , although PS binding could not be linked to the anti-viral activity of either papuamide A or B [90] .
Thiostrepton (Fig. 9g) , and the related molecule siomycin A, are antibiotics that inhibit prokaryotic translation [92] , but are also selectively cytotoxic to transformed eukaryotic cells. Siomycin A induced apoptosis in transformed, but not in normal lung fibroblasts, and it selectively killed breast cancer cells through inhibition of FOXM1 signaling [93] . Siomycin A also inhibited tumor growth from glioblastoma stem cells through down-regulation of maternal embryonic leucine zipper kinase (MELK) [94] . More recent studies showed that thiostrepton and siomycin A are both proteasome inhibitors and that this activity is responsible for their ability to decrease FOXM1 levels and selectively kill certain cancer cells [95, 96] . However, another group reported recently that the down-regulation of FOXM1 in malignant mesothelioma cells is not related to proteasome inhibition, but rather correlates with the ability of thiostrepton to disable the mitochondrial anti-oxidant pathway by covalently dimer- izing the protein peroxiredoxin 3 (PRX3) through thiostrepton's multiple dehydroalanine residues [97] .
Despite the conflicting hypotheses regarding the MOA of thiostrepton, its target(s) is/are likely intracellular. The Xray [98] and solution NMR [99] structures of thiostrepton show some intramolecular hydrogen bonding, but also a significant number of solvent-exposed polar groups, suggesting that thiostrepton is unlikely to traverse membranes by a simple passive diffusion-type mechanism. However, the lack of cationic residues suggests its mechanism of membrane penetration is distinct from the pore-forming and membranedisrupting mechanisms shared by the classical amphiphilic antimicrobial peptides.
Microcin J25 is a lariat "protoknot" peptide with a lactam linkage formed between the N-terminal Gly and an internal Glu side chain (Fig. 9h) . It inhibits bacterial transcription by blocking the nucleotide uptake channel of bacterial RNA polymerase [100, 101] , and has also been shown to increase superoxide production in bacteria. Microcin J25 also acts as a mitochondrial uncoupler and stimulates cytochrome C release from isolated, intact mammalian mitochondria [102, 103] , although it has minimal apoptotic activity in human cells in culture. In this remarkable structure, the "tail" portion of microcin J25 is threaded through and sterically trapped within the ring, forming a lasso topology [104, 105] .
The 21-residue compound is mostly hydrophobic and has numerous intramolecular hydrogen bonds, with a single His residue that forms an intramolecular side-chain-to-backbone hydrogen bond. It interacts with artificial liposome preparations, showing selectivity for zwitterionic over negatively charged phospholipids, and transports small ions across the membrane without causing membrane disruption [106, 107] . The interaction of microcin J25 with membranes has also been studied using Langmuir monolayers and was shown to be entropically favorable, suggesting that the classic hydrophobic effect may drive the thermodynamics of its partitioning into membranes [108] . 
Cyclotides and Cysteine-Knot Proteins
Cyclotides [109] are backbone-cyclized "microproteins" that contain multiple disulfide bonds and a conserved multiloop structure [110, 111] . Kalata B1, a plant-derived cyclotide with 29 amino acids and three disulfide bonds (Fig.  10a) , was discovered as the active constituent of a tea made from Oldenlandia affinis, used by midwives in Central Africa to stimulate uterine contractions [112] . Remarkably, kalata B1 is orally active, although its in vivo PK in animals has not been reported. It is therefore difficult to discern whether the oral activity of kalata B1 is due to good absorption, or rather is achieved despite poor absorption, for example, because of very high affinity for its pharmacological target. A classic example of this phenomenon is the clinical drug desmopressin, an orally delivered derivative of the cyclic peptide vasopressin that is used to treat diabetes insipidus, nocturia, and various coagulation disorders. Desmopressin has an absolute oral bioavailability of only 0.1% [113] and yet shows oral efficacy at doses as low as 100 g in adults. Such potent oral activity in the context of poor oral bioavailability can occur when a ligand has a very slow dissociation rate from its receptor, allowing the receptor to become fully occupied even though steady-state levels of the drug in serum remain very low [114] .
In studies using mammalian cell cultures, kalata B1 formed aggregates on the cell exterior. In the same study, a structurally similar cyclotide, MCoTI-II, was shown to penetrate cells by macropinocytosis [115] , an energy-dependent but receptor-independent mechanism of internalization known to operate with poly-Arg and other cell penetrating peptides such as Tat [116] . Nonetheless, solution NMR studies investigating the interaction of kalata B1 and other cyclotides with micelles have revealed that the cyclic peptides interact with membranes in a specific geometry that depends on the 3-dimensional arrangement of hydrophobic residues among the three loops [117, 118] . The cell permeability of cyclotides has been successfully applied to the design of orally active cyclotides with novel functions by grafting bioactive peptide sequences into cyclotide loops, suggesting that these proteins may be general scaffolds with which to design orally active molecules based on any bioactive peptide of interest [119] [120] [121] . Despite the intriguing oral activity of these compounds, however, their absolute oral bioavailability has not been reported.
Another disulfide-rich protein that has interesting pharmacokinetic properties is the soybean-derived 8 kD Bowman-Birk inhibitor (BBI; Fig. 10b)[122] . BBI is not backbone-cyclized, although like the cyclotides it has a knot-like topology [123, 124] . BBI suppressed radiation-induced transformation of pluripotent stem cells at sub-nM concentrations [125] , and when fed to mice prevented chemicalinduced adenocarcinoma [126] . Indeed, BBI was widely distributed in tissues within 3 hours after oral administration [127] . It retained full protease inhibitory activity after oral delivery and purification from serum and internal organs, indicating that in addition to its permeability it survived first pass metabolism intact and had both low metabolic clearance and minimal proteolytic degradation. However, whether BBI penetrates membranes by passive diffusion or some other mechanism (e.g. by receptor-mediated endocytosis) remains unknown, and its absolute oral biovailability has not been reported.
While the mechanism(s) of membrane permeation of the cysteine knot microproteins has not been firmly established, at first glance it would seem unlikely that these molecules penetrate cells by passive diffusion. If, however, cysteine knot microproteins such as kalata B1 and BBI prove to exhibit passive membrane permeability in a cell-free membrane permeability system, it will force us to re-evaluate the molecular weight barrier typically associated with passive membrane diffusion. These proteins are highly rigid, stabilized by C-to-N cyclization and multiple internal disulfide bonds, which allows them to adopt unusual folds in which the polar groups are buried (forming complex networks of hydrogen bonds) and multiple hydrophobic residues are exposed to solvent. Could the rigidity of these molecules coupled with their relatively large hydrophobic surfaces allow them to pass through membranes by a mechanism more akin to passive diffusion than the sort of direct, electrostatic interaction ascribed to the cationic antimicrobial peptides? NMR evidence showing the specific interaction of kalata B1 and other cyclotides with micelles [117, 118] points toward the possibility of passive diffusion for these molecules, although more studies are needed to establish a detailed mechanism of penetration. 
DISCUSSION
The cell permeability associated with many relatively large cyclic peptide natural products runs counter to "druglikeness" predictors applied to typical small molecules. These natural products thus provide excellent model systems with which to study ADME properties of large macrocycles, and perhaps for large, "non-Lipinski" molecules in general. 
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The observation that molecules like CSA and others can be cell permeable begs the question: What is the relationship between molecular weight and membrane permeability? If the number of rotatable bonds is indeed a better predictor of permeability than MW, this supports the notion of an entropic barrier to permeability that increases with increasing size. For example, transit through the ordered phospholipid bilayer may involve the freezing out of bond rotations with an associated entropic liability, while structurally rigid molecules are preorganized enough to avoid such an entropic cost. While the retrospective study by Veber et al. [18] , using a database of known drugs and their associated permeability supports this hypothesis, thermodynamic measurements using controlled model systems would provide an orthogonal means of testing the impact of entropy on permeability and its connection to molecular weight and/or rigidity. Current predictive models of permeability that take size into account [52] might benefit from measurements obtained on such "outlier" systems as these large cyclic peptides.
CSA has been by far the most intensively studied "nonpolar" cyclic peptide and is the only such molecule for which we have extensive pharmacokinetic data in humans. Although it is tempting to infer general principles based on CSA, its PK properties may not be generalizable to other cyclic peptides. For example, although there is strong evidence that CSA penetrates epithelial cells by passive diffusion [15] , it is also a substrate for the P-glycoprotein (Pgp) efflux pump and is actively transported from epithelial cells in the basolateral-to-apical direction [128] . Other non-polar cyclic peptides are also known P-glycoprotein substrates (and, like CSA, capable of reversing the multi-drug resistance due to Pgp overexpression) [129] , although it is unclear to what extent this observation can be further generalized. Further, the oral bioavailability and volume of distribution of CSA are highly variable in the population [130] , a function of patient-to-patient variability in activities and expression levels of Pgp as well as CYP3a, the major CYP involved in CSA metabolism [131, 132] . Whether this degree of variability holds for other non-polar cyclic peptides remains to be seen.
While we are beginning to learn about the connections between structure, molecular weight, and membrane permeability in cyclic peptides, we have only begun to scratch the surface in terms of the interplay of factors that determine PK in these large, functionally rich molecules. Indeed, few cyclic peptide natural products have been subjected to direct cell permeability measurements, much less in vivo PK studies. These studies would benefit not only from the traditional techniques used in this area (e.g. PAMPA and Caco-2 permeability), but also from the biophysical techniques that have been applied to the study of cationic antimicrobial peptides using defined, cell-free membrane systems. These include solid state NMR using 19 F and 15 N probes [133] , attenuated total reflection-Fourier transform infrared spectroscopy (ATR-FTIR) [134] and surface plasmon resonance (SPR) [135] . While these studies have shed light on the detailed interactions between pore-forming peptides and biological membranes, their application to the study of passive membrane diffusion by cyclic peptides has been limited. A more detailed biophysical model of passive membrane diffusion would likely benefit from an investigation into the structure-permeability relationship in these larger, "nonLipinski" molecules.
Chemists tend to assume that natural products were designed by evolution to carry out functions related primarily to defense or predation, although evidence is scant either in support of or against this hypothesis. Nonetheless, it would explain why natural products tend to target essential and highly conserved biological processes and structures such as protein synthesis, the cytoskeleton, and critical organelles, and similarly why natural products continue to be the logical source of leads in antimicrobial and anticancer drug discovery. This hypothesis has also led to the view that natural products may not be the best choice for leads against most other human disease targets, since humans did not co-evolve with the organisms that produce them. Indeed, a systemslevel study of the protein targets of natural products revealed that they tend to be more highly connected pathway "hubs" than human disease-related targets in general [136] .
Yet, while evolution may have selected natural products that inhibit a relatively narrow range of human disease targets, the realm of PK may represent a nexus where the constraints driving both natural product evolution and drug design converge. In terms of natural selection, the ability to cross biological membranes and avoid metabolic degradation, both oxidative and proteolytic, are likely to be just as important as binding affinity in the evolution of natural products. Large cyclic peptides, in particular, seem to have evolved tricks that allow them to push the PK envelope, maximizing size and complexity (toward greater potency) while maintaining good stability and membrane permeability. Thus, the design of combinatorial libraries of "natural product-like" molecules, which attempt to recapitulate the diversity and complexity of natural products without the target limitations set by natural selection, can perhaps be informed by the structural features shared by natural products which favor permeability and stability. For cyclic peptides, these features include general trends in side chain functionality, and also specific patterns of backbone stereochemistry and N-methylation, which permit or even stabilize membrane permeable conformations. Indeed, it is likely that cyclic peptide natural products will continue to inform our understanding of the relationship between structure and pharmacokinetics, especially as we attempt to design new molecules in the outer reaches of "drug-like" chemical space, for some time to come.
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